NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will release financial results for the fourth quarter and full year 2023 financials after the market close, and host a conference call at 4:30 PM Eastern Time on Tuesday, March 12, 2024.
Earnings call details are as follows:
Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 402294
Webcast: https://www.webcaster4.com/Webcast/Page/2879/49733
About iCAD
iCAD, Inc. (NASDAQ:ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD's industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more ...